Summit Therapeutics SMMT
NASDAQ SMMT
$16.88 -0.95 (-5.33%)
As of: Nov 11, 2026 · 1:01 PM EST

Summit Therapeutics (SMMT) Goodwill impairment charges (2018 - 2020)

Updated

Analysis

Summit Therapeutics (SMMT) Goodwill impairment charges (2018 - 2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Summit Therapeutics 14.26 Bn 11.63 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 859,000.00
Dec 31, 2019 5.12 Mn
Jul 31, 2018 -5.31 Mn
API Access

Summit Therapeutics Goodwill impairment charges API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=goodwill-impairment-charges&ticker=SMMT&period=max&api_key=YOUR_API_KEY